Skip to main content
Top
Published in: Rheumatology International 9/2008

01-07-2008 | Case Report

Henoch–Schonlein purpura with high factor VIII levels and deep venous thrombosis: an association or coincidence?

Authors: Rezan Topaloglu, Umut Selda Bayrakci, Barbaros Cil, Diclehan Orhon, Aysin Bakkaloglu

Published in: Rheumatology International | Issue 9/2008

Login to get access

Abstract

Henoch–Schonlein purpura (HSP) is the most common systemic vasculitis in children. Although long-term outcome is generally good, serious complications may occur. Thrombosis has been reported only as an extremely rare complication of HSP. Here, we describe a 15-year-old-boy with features of HSP, who developed left main iliac, external iliac and femoral vein thrombosis. Factor VIII (FVIII) and homocystein levels were found to be high. This suggests that HSP itself may lead to a prothrombotic state and increase the risk of developing thrombosis in patients who have any risk factors.
Literature
1.
go back to reference Garber ME, Mahr BE, Calabrese LH (1993) Henoch–Schonlein purpura associated with anti-Ro (SSA) and antiphospholipid antibody syndrome. J Rheumatol 20:1964–1966PubMed Garber ME, Mahr BE, Calabrese LH (1993) Henoch–Schonlein purpura associated with anti-Ro (SSA) and antiphospholipid antibody syndrome. J Rheumatol 20:1964–1966PubMed
2.
go back to reference Sokol DK, Mclntyre JA, Short RA, Gutt J, Wagenknecht DR, Biller J, Garg B (2000) Henoch–Schonlein purpura and stroke: antiphosphatdylethanolamine antibody in CSF and serum. Neurology 55:1379–1381PubMed Sokol DK, Mclntyre JA, Short RA, Gutt J, Wagenknecht DR, Biller J, Garg B (2000) Henoch–Schonlein purpura and stroke: antiphosphatdylethanolamine antibody in CSF and serum. Neurology 55:1379–1381PubMed
3.
go back to reference Sari I, Akar S, Secil M, Birlik M, Kefi A, Onen F, Celebi I, Akkoc N (2005) Thrombosis and priapism in a patient with Henoch–Schonlein purpura. Rheumatol Int 25:472–474PubMedCrossRef Sari I, Akar S, Secil M, Birlik M, Kefi A, Onen F, Celebi I, Akkoc N (2005) Thrombosis and priapism in a patient with Henoch–Schonlein purpura. Rheumatol Int 25:472–474PubMedCrossRef
4.
go back to reference Kamitsuji H, Tani K, Yasui M, Taniguchi A, Taira K, Tsukada S, Iida Y, Kanki H, Fukui H (1987) Activity of blood coagulation factor XIII as a prognostic indicator in patients with Henoch–Schonlein purpura. Eur J Pediatr 146:519–523PubMedCrossRef Kamitsuji H, Tani K, Yasui M, Taniguchi A, Taira K, Tsukada S, Iida Y, Kanki H, Fukui H (1987) Activity of blood coagulation factor XIII as a prognostic indicator in patients with Henoch–Schonlein purpura. Eur J Pediatr 146:519–523PubMedCrossRef
5.
go back to reference Culic S, Jakl R, Metlicic V, Paukovic-Sekulic B, Resic B, Culic V, Kuljis D, Primorac D (2001) Platelet function analysis in children with Schonlein–Henoch syndrome. Arch Med Res 32:268–272PubMedCrossRef Culic S, Jakl R, Metlicic V, Paukovic-Sekulic B, Resic B, Culic V, Kuljis D, Primorac D (2001) Platelet function analysis in children with Schonlein–Henoch syndrome. Arch Med Res 32:268–272PubMedCrossRef
6.
go back to reference De Mattia D, Penza R, Giardano P, Del Vecchio GC, Aceto G, Altomare M, Schettini F (1995) von Willebrand factor and factor XIII in children with Henoch–Schonlein purpura. Pediatr Nephrol 9:603–605PubMedCrossRef De Mattia D, Penza R, Giardano P, Del Vecchio GC, Aceto G, Altomare M, Schettini F (1995) von Willebrand factor and factor XIII in children with Henoch–Schonlein purpura. Pediatr Nephrol 9:603–605PubMedCrossRef
7.
go back to reference Prandota J, Pankow-Prandota L, Kotecki L (2001) Impaired activation of the fibrinolytic system in children with Henoch–Schonlein purpura: beneficial effect of hydrocortisone plus Sigma-aminocaproic acid therapy on disappearance rate of cutaneous vasculitis and fibrinolysis. Am J Ther 8:11–19PubMedCrossRef Prandota J, Pankow-Prandota L, Kotecki L (2001) Impaired activation of the fibrinolytic system in children with Henoch–Schonlein purpura: beneficial effect of hydrocortisone plus Sigma-aminocaproic acid therapy on disappearance rate of cutaneous vasculitis and fibrinolysis. Am J Ther 8:11–19PubMedCrossRef
8.
go back to reference Brendel-Muller K, Hahn A, Schneppenheim R, Santer R (2001) Laboratory signs of activated coagulation is common in Henoch-purpura. Pediatr Nephrol 16:1084–1088PubMedCrossRef Brendel-Muller K, Hahn A, Schneppenheim R, Santer R (2001) Laboratory signs of activated coagulation is common in Henoch-purpura. Pediatr Nephrol 16:1084–1088PubMedCrossRef
9.
go back to reference Besbas N, Erbay A, Saatci U (1998) Thrombomodulin, tissue plasminogen activator and plasminogen activator inhibitor-1 in Henoch-purpura. Clin Exp Rheumatol 16:95–98PubMed Besbas N, Erbay A, Saatci U (1998) Thrombomodulin, tissue plasminogen activator and plasminogen activator inhibitor-1 in Henoch-purpura. Clin Exp Rheumatol 16:95–98PubMed
10.
go back to reference Yilmaz D, Kavakli K, Ozkayin N (2005) The elevated markers of hypercoagulability in childrenwith Henoch–Schonlein purpura. Pediatr Hematol Oncol 22:41–48PubMedCrossRef Yilmaz D, Kavakli K, Ozkayin N (2005) The elevated markers of hypercoagulability in childrenwith Henoch–Schonlein purpura. Pediatr Hematol Oncol 22:41–48PubMedCrossRef
11.
go back to reference Ates E, Bakkaloglu A, Saatci U, Soylemezoglu O (1994) von Willebrand factor antigen compared with other factors in vasculitic syndromes. Arch Dis Child 70:40–43PubMedCrossRef Ates E, Bakkaloglu A, Saatci U, Soylemezoglu O (1994) von Willebrand factor antigen compared with other factors in vasculitic syndromes. Arch Dis Child 70:40–43PubMedCrossRef
12.
go back to reference Kiraz S, Ertemli I, Ozturk MA, Haznedaroglu IC, Celik I, Calguneri M (2002) Pathological Haemostasis and ‘protrombotic state’ in Behcet’s Disease. Thromb Res 105:125–133PubMedCrossRef Kiraz S, Ertemli I, Ozturk MA, Haznedaroglu IC, Celik I, Calguneri M (2002) Pathological Haemostasis and ‘protrombotic state’ in Behcet’s Disease. Thromb Res 105:125–133PubMedCrossRef
13.
go back to reference Kurekci AE, Gokce H, Akar N (2003) Factor VIII levels in children with thrombosis. Pediatr Int 45:159–162PubMedCrossRef Kurekci AE, Gokce H, Akar N (2003) Factor VIII levels in children with thrombosis. Pediatr Int 45:159–162PubMedCrossRef
14.
go back to reference Rosendaal FR (2000) High levels of factor VIII, venous thrombosis. Thromb Haemost 83:1–2PubMed Rosendaal FR (2000) High levels of factor VIII, venous thrombosis. Thromb Haemost 83:1–2PubMed
15.
go back to reference Selhub J, D’Angelo A (1997) Hyperhomocysteinemia and thrombosis: Acquired conditions. Thromb Haemost 78:527–531PubMed Selhub J, D’Angelo A (1997) Hyperhomocysteinemia and thrombosis: Acquired conditions. Thromb Haemost 78:527–531PubMed
Metadata
Title
Henoch–Schonlein purpura with high factor VIII levels and deep venous thrombosis: an association or coincidence?
Authors
Rezan Topaloglu
Umut Selda Bayrakci
Barbaros Cil
Diclehan Orhon
Aysin Bakkaloglu
Publication date
01-07-2008
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 9/2008
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-008-0542-7

Other articles of this Issue 9/2008

Rheumatology International 9/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.